Angela Cacace’s Post

Paul Hyslop, from ARKLEY BIOTEK LLC Indianapolis, details an ongoing specific research approach to identify, characterize, and validate physiologically relevant neuronal targets of #H2O2 in designing therapeutics for #neurodegenerative disease progression The societal impact of #dementia resulting from the major neurodegenerative diseases such as #Alzheimer’s presents a growing and significant unmet medical need. (1) Various cellular #metabolic and structural deficits, neuroinflammation, and oxidative stress are known to result in the progressive loss of vulnerable non-regenerative #neurons. (2) Find out more here: https://bit.ly/3SZPklr

A new molecule improves brain function in Alzheimer's mice by modulating neuronal communication and transcriptomic immune response, according to new research funded by the Knight Initiative. Targeting TrkB/C receptors may lead to future treatments for AD. https://lnkd.in/gyY6WGFK

𝗜 𝗹𝗼𝘃𝗲 𝘄𝗵𝗲𝗻 𝗲𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀 𝗳𝗶𝗻𝗱 𝗻𝗲𝘄 𝘂𝘀𝗲𝘀! 👩🔬 Researchers have discovered that an 𝗮𝗻𝘁𝗶-𝗻𝗮𝘂𝘀𝗲𝗮 𝗱𝗿𝘂𝗴 may help fight 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 by reducing the activation of astrocytes, brain cells involved in the inflammatory processes seen in Alzheimer’s disease. 🔬 The drug specifically prevents astrocytes from becoming overactive, which is critical because overactivation contributes to the neurodegenerative process. The study conducted in mice showed that astrocytes, when overactive, can damage surrounding neurons, leading to cognitive decline and memory loss. By calming astrocytes down, the drug helped preserve brain function and slow disease progression. 🧠 Astrocytes typically support neurons, but in Alzheimer's, they become harmful by releasing inflammatory molecules. Reducing this inflammation is key to stopping further brain damage. The research team found that the drug restored normal behavior in the mice, preventing the loss of communication between neurons 🙌 This finding could make existing anti-nausea drugs a candidate for Alzheimer's treatment, offering a faster path to human trials due to their already established safety profiles. https://lnkd.in/eg_EBMrj #DrugRepurposing #AlzheimersResearch #Neuroinflammation #AstrocyteScience #BrainHealth

Thrilled to share that our research article, "In Vitro Neuroprotective Effect Evaluation of Donepezil-Loaded PLGA Nanoparticles-Embedded PVA/PEG Nanofibers on SH-SY5Y Cells and AP-APP Plasmid Related Alzheimer Cell Line Model" has been accepted for publication! 🧠🔬 This study explores a novel drug delivery system for Donepezil, a medication used to treat Alzheimer's disease. By encapsulating Donepezil in PLGA nanoparticles embedded within PVA/PEG nanofibers, we aim to enhance its efficacy and potentially improve treatment outcomes. We investigated the neuroprotective effects of this system on SH-SY5Y cells and an AP-APP plasmid-related Alzheimer cell line model. Our findings shed light on the potential of this innovative approach for Alzheimer's treatment. #AlzheimersResearch #DrugDelivery #Nanotechnology #Neuroprotection #ScientificPublication Muhammet Emin Cam, Ece Guler, Professor Deepak Kalaskar https://lnkd.in/gW8KCx93

Preclinical model offers new insights into Parkinson's disease process https://lnkd.in/eCdraa7e

New research from the University of Toronto, led by Dr Jen Gommerman and Angela Wang, suggests that B cell therapies may also have a neuroprotective effect in multiple sclerosis. Their study has highlighted a potential role for a protein called B cell survival factor, or BAFF, in this process. Further research will now be conducted to understand how these molecules contribute to neuroprotection in MS. #multiplesclerosis #neuroprotection #bcells

🚩#SpecialIssue 🙋♂️Call for Papers 🙋♀️ 🎯Breakthroughs in #Mechanisms and #Treatments for #Neurodegenerative Diseases ⏰Submission Deadline: December 31, 2024 👥Guest Editors: Dr. Rong Ma, Dr. Guoku Hu 📩 For submission or inquiry, please contact entjournal@explorationpub.com This special issue features groundbreaking research and innovative approaches that enhance our understanding of neurodegenerative disease mechanisms and explore novel therapeutic interventions. Contributions span a diverse range of topics, including molecular pathways, protein aggregation dynamics, cellular signaling cascades, neuroinflammation mechanisms, synaptic dysfunction, immunotherapy, and neuronal regeneration strategies. Additionally, we explore emerging technologies such as extracellular vesicle therapy, gene editing techniques, advanced neuroimaging modalities, and biomarker discovery for early diagnosis and treatment monitoring. Keywords #neurodegenerative diseases #Alzheimer's disease #Parkinson's disease #amyotrophic lateral sclerosis #ALS #neuroinflammation #biomarker discovery #immunotherapy #extracellular vesicle Learn more at https://lnkd.in/eUMz-vme

June is Alzheimer’s and Brain Awareness Month. To demonstrate NYU’s continued commitment to developing new therapeutics for neurodegenerative diseases, Einar Sigurdsson’s Lab at NYU Langone Health recently published its most recent data on synucleinopathies in a high-impact neuroscience journal. The study focuses on using a novel approach of single-domain antibody degraders to drive the destruction of a protein called α-synuclein involved in #ParkinsonsDisease. This is a major step forward in terms of in vivo experiments showing that this kind of antibody-based therapy has clinical potential. 📖 Read the paper: https://lnkd.in/ePFrHkuc 🤝 Learn more about this exciting technology and how you could partner with us ➡ https://lnkd.in/eZV-g6KM or contact business development manager Amit Duvshani, PhD or licensing associate Olivia Zelony, Candidate RTTP. #ParkinsonsDisease #synucleinopathies #antibody #AlzheimersAwarenessMonth #BrainAwarenessMonth #neurodegenerativediseases #neurodegenerative

𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐲𝐨𝐮𝐫 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐨𝐟 𝐧𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐚𝐭 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟒! ⚕️ Day Two Track 3 will discuss 'Drug Discovery for Neurodegenerative Diseases' with insights from Janet Brownlees FRSB, Morten Grunnet, Prof, PhD, DrSci, Graham T. Dempsey, Anto Pavlovic. Peter Brandt, David Bearss Ph.D., Ashutosh Dhingra, Julian Röwe and Borislav Dejanovic! 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐓𝐨𝐩𝐢𝐜𝐬: 📌 Target identification and validation approaches 📌 Stem cell technology to fuel drug discovery 📌 iPS cells for disease modelling and drug discovery 📌 In vitro and in vivo disease modelling 📌 Targeting and regulating neuroinflammation 📌 Neurodegenerative & Neuroinflammation/Immunology models for robust drug discovery ▶️ Get all details: https://hubs.la/Q02xfXYX0 #OGDiscovery #DiscoveryEU24 #DrugDiscovery #NeurodegenerativeDiseases

As I was finding more information for a third post on Alzheimer's targeted therapies, I saw the recent news on a development from Korean scientists who engineered an exosome-based delivery system, MAPLEX. This novel system enables delivery of protein-based therapies to specific cells, using the natural function of exosomes, by engineering them to carry a therapeutic protein, which reduced amyloid-beta levels via epigenetic editing. A complexed process with promising results in Alzheimer's disease mouse models but more research and refining is needed for the future translation of this therapy into humans. Quote from the paper below and link to the study in comments. "This approach led to a significant reduction in Bace1 expression, improved recognition memory impairment, and reduced amyloid pathology in 5xFAD and 3xTg-AD mice. These results suggest that MAPLEX is an efficient intracellular protein delivery system that can deliver diverse therapeutic proteins for multiple diseases."